A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (PNEU-FLU)
Phase of Trial: Phase III
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs GSK 2321138A (Primary) ; V 114 (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms PNEU-FLU
- Sponsors Merck Sharp & Dohme
- 03 Jul 2019 Status changed from active, no longer recruiting to completed.
- 26 Feb 2019 Planned End Date changed from 17 Jun 2019 to 24 Jun 2019.
- 26 Feb 2019 Planned primary completion date changed from 17 Jun 2019 to 24 Jun 2019.